Clinton Bybee's Net Worth
$2.01 Billion
Who is Clinton Bybee?
Clinton Bybee has an estimated net worth of $2.01 Billion. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., KYTHERA BIOPHARMACEUTICALS INC, PHASERX, INC., Neumora Therapeutics, Inc., Lyell Immunopharma, Inc., ADESTO TECHNOLOGIES Corp, AGIOS PHARMACEUTICALS INC, NeurogesX Inc, VBI VACCINES INC., Receptos, Inc., Gossamer Bio, Inc., Scholar Rock Holding Corp, Pulmatrix, Inc., Karuna Therapeutics, Inc., bluebird bio, Inc., Denali Therapeutics Inc., FATE THERAPEUTICS INC, Sage Therapeutics, Inc., Vir Biotechnology, Inc., Beam Therapeutics Inc., Metacrine, Inc., Bellerophon Therapeutics, Inc., Unity Biotechnology, Inc., Syros Pharmaceuticals, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Juno Therapeutics, Inc., Homology Medicines, Inc., Achaogen Inc, Trubion Pharmaceuticals, Inc, CELEBRATE EXPRESS, INC., 908 Devices Inc., Quanterix Corp, Twist Bioscience Corp, XTERA COMMUNICATIONS, INC., ALNYLAM PHARMACEUTICALS INC, IMPINJ INC, XCYTE THERAPIES INC, and ILLUMINA INC.
SEC CIK
Clinton Bybee's CIK is 0001219043
Past Insider Trading and Trends
2021 was Clinton Bybee's most active year for acquiring shares with 43 total transactions. Clinton Bybee's most active month to acquire stocks was the month of July. 2021 was Clinton Bybee's most active year for disposing of shares, totalling 48 transactions. Clinton Bybee's most active month to dispose stocks was the month of September. 2023 saw Clinton Bybee paying a total of $25,500,000.00 for 18,924,704 shares, this is the most they've acquired in one year. In 2012 Clinton Bybee cashed out on 2,308,783 shares for a total of $919,768.08, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Sana Biotechnology, Inc. (SANA) Snapshot price: $6.175
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +5.39% | 1.82M |
$5.50 | $9,999,995.50 | 35.56M |
Feb 8
| |||
Form 4
| +14,957.26% | 43.75M |
—
|
—
| 44.04M |
Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
KYTHERA BIOPHARMACEUTICALS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.11M |
$13.72 | -$919,768.08 | 2.11M |
Oct 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
PHASERX, INC. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +12.62% | 319.94K |
$2.51 | $4,993,199.41 | 2.85M |
May 23
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Neumora Therapeutics, Inc. (NMRA) Snapshot price: $17.03
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +102.76% | 1.88M |
—
|
—
| 3.71M |
Dec 8
| |||
Form 4
| +178.19% | 18.92M |
$17.00 |
—
| 29.55M |
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Lyell Immunopharma, Inc. (LYEL) Snapshot price: $1.76
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 36.41M |
—
|
—
| 36.41M |
Jun 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |